169 related articles for article (PubMed ID: 32632769)
21. Mifepristone inhibits IGF-1 signaling pathway in the treatment of uterine leiomyomas.
Shen Q; Zou S; Sheng B; Zhao M; Sun LZ; Zhu X
Drug Des Devel Ther; 2019; 13():3161-3170. PubMed ID: 31564832
[TBL] [Abstract][Full Text] [Related]
22. 1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model.
Halder SK; Sharan C; Al-Hendy A
Biol Reprod; 2012 Apr; 86(4):116. PubMed ID: 22302692
[TBL] [Abstract][Full Text] [Related]
23. Comparative effects of heparin-binding epidermal growth factor-like growth factor on the growth of cultured human uterine leiomyoma cells and myometrial cells.
Wang J; Ohara N; Takekida S; Xu Q; Maruo T
Hum Reprod; 2005 Jun; 20(6):1456-65. PubMed ID: 15760954
[TBL] [Abstract][Full Text] [Related]
24. Simvastatin modulates estrogen signaling in uterine leiomyoma via regulating receptor palmitoylation, trafficking and degradation.
Afrin S; El Sabeh M; Islam MS; Miyashita-Ishiwata M; Malik M; Catherino WH; Akimzhanov AM; Boehning D; Yang Q; Al-Hendy A; Segars JH; Borahay MA
Pharmacol Res; 2021 Oct; 172():105856. PubMed ID: 34461224
[TBL] [Abstract][Full Text] [Related]
25. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth.
Yoshida S; Ohara N; Xu Q; Chen W; Wang J; Nakabayashi K; Sasaki H; Morikawa A; Maruo T
Semin Reprod Med; 2010 May; 28(3):260-73. PubMed ID: 20414849
[TBL] [Abstract][Full Text] [Related]
26. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas.
Vu K; Greenspan DL; Wu TC; Zacur HA; Kurman RJ
Hum Pathol; 1998 Apr; 29(4):359-63. PubMed ID: 9563785
[TBL] [Abstract][Full Text] [Related]
27. EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.
Nair HB; Santhamma B; Dileep KV; Binkley P; Acosta K; Zhang KYJ; Schenken R; Nickisch K
Sci Rep; 2019 Nov; 9(1):17279. PubMed ID: 31754172
[TBL] [Abstract][Full Text] [Related]
28. Nanomedicine for uterine leiomyoma therapy.
Ali H; Kilic G; Vincent K; Motamedi M; Rytting E
Ther Deliv; 2013 Feb; 4(2):161-75. PubMed ID: 23343157
[TBL] [Abstract][Full Text] [Related]
29. The anticancer effects of 2-methoxyestradiol on human huh7 cells in vitro and in vivo.
Tao H; Mei J; Tang X
Biochem Biophys Res Commun; 2019 May; 512(3):635-640. PubMed ID: 30914193
[TBL] [Abstract][Full Text] [Related]
30. Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women.
Palomba S; Orio F; Russo T; Falbo A; Tolino A; Lombardi G; Cimini V; Zullo F
Fertil Steril; 2005 Jul; 84(1):154-61. PubMed ID: 16009171
[TBL] [Abstract][Full Text] [Related]
31. Fibroid growth and medical options for treatment.
Chabbert-Buffet N; Esber N; Bouchard P
Fertil Steril; 2014 Sep; 102(3):630-9. PubMed ID: 25171950
[TBL] [Abstract][Full Text] [Related]
32. Locostatin, a disrupter of Raf kinase inhibitor protein, inhibits extracellular matrix production, proliferation, and migration in human uterine leiomyoma and myometrial cells.
Janjusevic M; Greco S; Islam MS; Castellucci C; Ciavattini A; Toti P; Petraglia F; Ciarmela P
Fertil Steril; 2016 Nov; 106(6):1530-1538.e1. PubMed ID: 27565262
[TBL] [Abstract][Full Text] [Related]
33. Nonobese diabetic/severe combined immunodeficient murine xenograft model for human uterine leiomyoma.
Wang G; Ishikawa H; Sone K; Kobayashi T; Kim JJ; Kurita T; Shozu M
Fertil Steril; 2014 May; 101(5):1485-92. PubMed ID: 24636398
[TBL] [Abstract][Full Text] [Related]
34. Wnt/β-catenin signaling pathway in uterine leiomyoma: role in tumor biology and targeting opportunities.
El Sabeh M; Saha SK; Afrin S; Islam MS; Borahay MA
Mol Cell Biochem; 2021 Sep; 476(9):3513-3536. PubMed ID: 33999334
[TBL] [Abstract][Full Text] [Related]
35. Development and Validation of Hormonal Impact of a Mouse Xenograft Model for Human Uterine Leiomyoma.
Malik M; Britten J; Catherino WH
Reprod Sci; 2020 Jun; 27(6):1304-1317. PubMed ID: 32016804
[TBL] [Abstract][Full Text] [Related]
36. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
Murphy AA; Kettel LM; Morales AJ; Roberts VJ; Yen SS
J Clin Endocrinol Metab; 1993 Feb; 76(2):513-7. PubMed ID: 8432797
[TBL] [Abstract][Full Text] [Related]
37. Involvement of Bcl-2, Src, and ERα in gossypol-mediated growth inhibition and apoptosis in human uterine leiomyoma and myometrial cells.
ZHU Y; XIE SW; ZHANG JF; ZHANG TT; ZHOU JY; CAO Y; CAO L
Acta Pharmacol Sin; 2010 Dec; 31(12):1593-603. PubMed ID: 21102482
[TBL] [Abstract][Full Text] [Related]
38. Biological and Mechanistic Characterization of Novel Prodrugs of Green Tea Polyphenol Epigallocatechin Gallate Analogs in Human Leiomyoma Cell Lines.
Ahmed RS; Liu G; Renzetti A; Farshi P; Yang H; Soave C; Saed G; El-Ghoneimy AA; El-Banna HA; Foldes R; Chan TH; Dou QP
J Cell Biochem; 2016 Oct; 117(10):2357-69. PubMed ID: 26950525
[TBL] [Abstract][Full Text] [Related]
39. Paricalcitol, a vitamin d receptor activator, inhibits tumor formation in a murine model of uterine fibroids.
Halder SK; Sharan C; Al-Hendy O; Al-Hendy A
Reprod Sci; 2014 Sep; 21(9):1108-19. PubMed ID: 24925855
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory effect of curcumin on uterine leiomyoma cell proliferation.
Tsuiji K; Takeda T; Li B; Wakabayashi A; Kondo A; Kimura T; Yaegashi N
Gynecol Endocrinol; 2011 Jul; 27(7):512-7. PubMed ID: 20672906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
